UPCC 01517: A Phase 1B/2 Study of Viagenpumatucel-L (HS-110) in Combination with Multiple Treatment Regimens in Patients with Non-Small Cell Lung Cancer (The DURGA Trial)

UPCC 01517: A Phase 1B/2 Study of Viagenpumatucel-L (HS-110) in Combination with Multiple Treatment Regimens in Patients with Non-Small Cell Lung Cancer (The DURGA Trial)
99 years or below
All
Phase 2
1 Location

Brief description of study

Request for collaborative review: MaGil IRB serving as IRB of record.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 826950

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.